Oncology
Dr. Rahul Verma
Recent Articles
28 totalOncology
USPSTF Updates BRCA Testing Guidelines: Who to Screen for Breast and Ovarian Cancer
USPSTF updates BRCA testing guidelines: who to screen for breast and ovarian cancer risk assessment.
Oncology
Zilovertamab Vedotin Shows Promising Results in CLL: 40% ORR in Phase II Trial
Zilovertamab vedotin shows 40% ORR in CLL, highlighting ADC potential in oncology.
Oncology
FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC: 45% ORR in Advanced Patients
Datopotamab deruxtecan approved for EGFR-mutated NSCLC: 45% ORR in advanced patients.
Oncology
Intismeran Autogene Cuts Melanoma Relapse 49% at 5 Years
Intismeran autogene reduces melanoma recurrence by 49% at five years, providing significant implications for treatment in stage III melanoma.
Oncology
Harnessing mRNA Vaccine Technology: A New Frontier in Cancer Immunotherapy
Explore the potential of mRNA vaccines in cancer immunotherapy, highlighting advancements and clinical implications for patient care.
Pharmaceutical Research
AI-Powered Drug Discovery: Transforming Treatment for Rare Diseases
Explore how AI is transforming drug discovery for rare diseases, improving efficiency and patient outcomes in pharmaceutical research.
Oncology
Talotrectinib Receives FDA Approval for ROS1+ NSCLC: A New Era in Targeted Therapy
Talotrectinib approved for ROS1+ NSCLC, offering new hope with high response rates and favorable safety profile.
Health Information
Boost Orthodontic Success with Proper Oral Hygiene
Learn how to maintain dental health during orthodontic treatment and prevent complications for a successful outcome and healthy smile.
Oncology
Reduce EGFRm NSCLC Dermatologic Toxicities by 30%
Proactive management approaches can minimize EGFR-related skin toxicities, improving quality of life for NSCLC patients on chemotherapy-free regimens.
Oncology
Triples Therapy Boosts PFS in ES-SCLC Maintenance
Discover how a triplet regimen improves progression-free survival in extensive-stage small cell lung cancer patients, enhancing maintenance therapy outcomes.
Oncology
ctDNA Surveillance Cuts CRC Recurrence Risk
New data reveals 80% of ctDNA-positive CRC patients experience molecular recurrence within 12-15 months, highlighting need for ongoing surveillance and potential early resistance t...
Oncology
Cut Ovarian Cancer Detection Costs with Risk-Based Triage
Improve ovarian cancer detection in primary care with cost-effective risk-based triage strategies, reducing unnecessary tests and improving patient outcomes.